Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feliu

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Current Cancer Drug Targets|January 11, 2012
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapyP Cejas, M López-Gómez, C Aguayo, et al.
British Journal of Cancer|April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II studyJ Feliu, A Salud, P Escudero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2020
Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapyD Viñal, L Gutierrez-Sainz, D Martinez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 1, 2005
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epitheliumP Cejas, M A García-Cabezas, E Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group studyA Custodio, J Moreno-Rubio, J Aparicio, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Free Radical Research|May 23, 2007
Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinomaP Cejas, M A García-Cabezas, E Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancerJ A Ajani, M Abramov, I Bondarenko, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 4, 2020
Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomasD Viñal, D Martinez, J A Garcia-Cuesta, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Current Cancer Drug Targets|January 11, 2012
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapyP Cejas, M López-Gómez, C Aguayo, et al.
British Journal of Cancer|April 15, 2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II studyJ Feliu, A Salud, P Escudero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2020
Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapyD Viñal, L Gutierrez-Sainz, D Martinez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 1, 2005
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epitheliumP Cejas, M A García-Cabezas, E Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group studyA Custodio, J Moreno-Rubio, J Aparicio, et al.
British Journal of Cancer|June 20, 2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyJ Feliu, A Salud, M J Safont, et al.
Free Radical Research|May 23, 2007
Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinomaP Cejas, M A García-Cabezas, E Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancerJ A Ajani, M Abramov, I Bondarenko, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 4, 2020
Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomasD Viñal, D Martinez, J A Garcia-Cuesta, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trialEstela Pineda, A Salud, E Vila-Navarro, et al.
Pageof 15